Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650702 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Mati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00650702 is a Phase 2 study that has completed, run by Mati Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT00650702, a Phase 2 study, has completed, sponsored by Mati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the Punctum Plug Delivery System (PPDS) is safe and effective in controlling intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Latanoprost-PPDS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650702
The ClinicalTrials.gov registry entry for NCT00650702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mati Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Latanoprost-PPDS is the first listed.
NCT00650702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650702 about?
NCT00650702 is a clinical study titled "Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to determine if the Punctum Plug Delivery System (PPDS) is safe and effective in controlling intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00650702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-03. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00650702?
The interventions under investigation include: Latanoprost-PPDS (DRUG).
Who is sponsoring clinical trial NCT00650702?
This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.